Interestingly, osimertinib was quite recently approved as a first-line treatment for patients with metastatic EGFR-mutant NSCLC previously untreated [21] and also as an adjuvant treatment for NSCLC with EGFR Ex19del or L858R mutations for stages IB−IIIA [22]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.